4.8 Article

Human airway branch variation and chronic obstructive pulmonary disease

Publisher

NATL ACAD SCIENCES
DOI: 10.1073/pnas.1715564115

Keywords

airway branching; fibroblast growth factor; chronic obstructive pulmonary disease; computed tomography

Funding

  1. NIH/NHLBI [HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN268200900019C]
  2. AstraZeneca
  3. Bellerophon Pharmaceuticals
  4. Boehringer-Ingelheim Pharmaceuticals, Inc.
  5. Chiesi Farmaceutici SpA
  6. Forest Research Institute, Inc.
  7. GlaxoSmithKline
  8. Grifols Therapeutics, Inc.
  9. Ikaria, Inc.
  10. Nycomed GmbH
  11. Takeda Pharmaceutical Company
  12. Novartis Pharmaceuticals Corporation
  13. Regeneron Pharmaceuticals, Inc.
  14. Sanofi
  15. NIH/NHLBI
  16. McGill University Health Center Research Institute
  17. Fonds de la recherche en sante Quebec (Quebec Health Research Fund)
  18. [HHSN268200900020C]
  19. [R01-HL130506]
  20. [R01-HL077612]
  21. [R01-HL093081]
  22. [R01-HL112986]
  23. [RC1HL100543]
  24. [RD831697]
  25. [N01-HC-95159]
  26. [N01-HC-95160]
  27. [N01-HC-95169]
  28. [N01-HC-95162]
  29. [N01-HC-95164]
  30. [U01-HL114494]
  31. [N01-HC95159-HC95169]
  32. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077612, R01HL093081, R43HL095167, R44HL095169, R35HL135834, RC1HL100543, R01HL095163, R13HL095166, R43HL095161, R01HL112986, R43HL095160, R01HL121270, R21HL095165, U01HL114494, R43HL095169, R01HL130506, U01HL137880, K24HL137013] Funding Source: NIH RePORTER
  33. NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK054759] Funding Source: NIH RePORTER
  34. NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009089, P30ES005605] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Susceptibility to chronic obstructive pulmonary disease (COPD) beyond cigarette smoking is incompletely understood, although several genetic variants associated with COPD are known to regulate airway branch development. We demonstrate that in vivo central airway branch variants are present in 26.5% of the general population, are unchanged over 10 y, and exhibit strong familial aggregation. The most common airway branch variant is associated with COPD in two cohorts (n = 5,054), with greater central airway bifurcation density, and with emphysema throughout the lung. The second most common airway branch variant is associated with COPD among smokers, with narrower airway lumens in all lobes, and with genetic polymorphisms within the FGF10 gene. We conclude that central airway branch variation, readily detected by computed tomography, is a biomarker of widely altered lung structure with a genetic basis and represents a COPD susceptibility factor.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available